Requip now has a competitor. The National Sleep Foundation reports that Mirapex has been approved for the treatment of RLS:
The Food and Drug Administration (FDA) has approved Mirapex for the treatment of moderate-to-severe primary restless legs syndrome (RLS), a common condition in which an irresistible urge to move the legs impacts a person’s quality of life and ability to sleep. A recent analysis of NSF’s 2005 Sleep in America poll published in the journal CHEST found that 9.7% of adults reported symptoms of RLS at least a few times a week.
Mirapex is made by Boehringer-Ingelheim and since 1997 has been indicated for treatment of symptoms of Parkinson’s disease. In clinical trials it was shown that lower doses (than used for Parkinson’s disease) improve RLS symptoms, sleep satisfaction, and quality of life. Side effects of the drug may include hallucinations, dizziness, sweating, and nausea and Boehringer-Ingelheim warns that Mirapex may cause patients to fall asleep without any warning, even while doing normal daily activities such as driving.